Effect of vitamin D supplementation on metabolic syndrome in elderlies

The Effect of Vitamin D Supplementation on Metabolic Syndrome Indicators among Food In-secured, Vitamin D Deficient ; A Randomised Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016121831449N1

Enrollment

120

Registered

2017-05-08

Start date

2017-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome (diabetes, obesity, blood pressure and hyperlipidemia). Metabolic disorders and nutritional

Interventions

Intervention 1: Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health. Intervention 2: Contr

Treatment - Drugs

Placebo

Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.

Control group: The respondents in control group will receive placebo per week for 8 weeks. Plus brochures and pamphlets related to nutrition and health at the beginning of the study.

Eligibility

Sex/Gender

All

Age

60 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Food insecure, waist Circumference>90 cm, body mass index =30 kg/m2, fasting blood sugar>100 mg/dl, high blood pressure (systolic >135 mmHg and diastolic >85 mmHg) and dyslipidaemia (Low density lipoprotein= 240 mg/dl, high density lipoprotein<40 mg/dl, total cholesterol= 160 mg/dl, triglyceride = 200 mg/dl), serum 25(OH) D level <30 ng/ml, no use of vitamin D supplementation before 60 days. Exclusion criteria: An inability or unwillingness to participate, those who are already taking any type of vitamin D supplements, Individuals with a history of allergy, those subjects with serious medical condition such as cancer, heart attack, stroke, and etc., illness that required corticosteroids or insulin, drugs are known to influence vitamin D level, steroids, anti-acids, oestrogen, people with conditions that contradict vitamin D supplementation, for example, a history of hypocalcaemia, hepatic disease or renal stones, sarcoidosis, or malignancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
25(OH)D. Timepoint: 8 weeks. Method of measurement: blood taking (before intervention and after intervention, 2 months later).	—

Secondary

Measure	Time frame
Fasting Blood Pressure (FBS). Timepoint: 8 weeks. Method of measurement: blood taking before and after intervention (2months).;Antropometrics indicators. Timepoint: 8 weeks. Method of measurement: measuring height and weight before and after intervention (2months).;Blood Pressure. Timepoint: 8 weeks. Method of measurement: measure before and after intervention (2months).;Hyperlipidemia. Timepoint: 8 weeks. Method of measurement: blood taking before and after intervention (2months).	—

Measure

Time frame

Fasting Blood Pressure (FBS). Timepoint: 8 weeks. Method of measurement: blood taking before and after intervention (2months).;Antropometrics indicators. Timepoint: 8 weeks. Method of measurement: measuring height and weight before and after intervention (2months).;Blood Pressure. Timepoint: 8 weeks. Method of measurement: measure before and after intervention (2months).;Hyperlipidemia. Timepoint: 8 weeks. Method of measurement: blood taking before and after intervention (2months).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Qorbani

Alborz Medical university

mqorbani1379@yahoo.com+98 912 585 5021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026